467 related articles for article (PubMed ID: 26289239)
1. [Underlying Mechanisms and Management of Refractory Gastroesophageal Reflux Disease].
Lee KJ
Korean J Gastroenterol; 2015 Aug; 66(2):70-4. PubMed ID: 26289239
[TBL] [Abstract][Full Text] [Related]
2. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
4. Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia?
Bashashati M; Hejazi RA; Andrews CN; Storr MA
Can J Gastroenterol Hepatol; 2014 Jun; 28(6):335-41. PubMed ID: 24719900
[TBL] [Abstract][Full Text] [Related]
5. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
Lee KJ; Kwon HC; Cheong JY; Cho SW
Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
[TBL] [Abstract][Full Text] [Related]
6. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease.
Kohata Y; Fujiwara Y; Yamagami H; Tanigawa T; Shiba M; Watanabe K; Watanabe T; Tominaga K; Arakawa T
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():36-40. PubMed ID: 25827802
[TBL] [Abstract][Full Text] [Related]
8. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
Schey R; Alla SP; Midani D; Parkman HP
Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
[TBL] [Abstract][Full Text] [Related]
9. Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors.
Matsumura T; Sonoda M; Okimoto K; Dao HV; Takahashi S; Akizue N; Horio R; Goto C; Kurosugi A; Kaneko T; Ohta Y; Taida T; Kikuchi A; Fujie M; Kato J; Kato N
Dig Dis Sci; 2024 Jun; 69(6):2132-2139. PubMed ID: 38622462
[TBL] [Abstract][Full Text] [Related]
10. Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment.
Spechler SJ
Gastroenterol Clin North Am; 2020 Sep; 49(3):437-450. PubMed ID: 32718563
[TBL] [Abstract][Full Text] [Related]
11. [Non-erosive reflux disease: NERD].
Kasugai K; Funaki Y; Ebi M; Ogasawara N; Sasaki M
Nihon Rinsho; 2015 Jul; 73(7):1105-9. PubMed ID: 26165065
[TBL] [Abstract][Full Text] [Related]
12. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
Pace F; Pace M
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
[TBL] [Abstract][Full Text] [Related]
13. Nonerosive reflux disease.
Long JD; Orlando RC
Minerva Gastroenterol Dietol; 2007 Jun; 53(2):127-41. PubMed ID: 17557041
[TBL] [Abstract][Full Text] [Related]
14. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
16. Precise role of acid in non-erosive reflux disease.
Wang C; Hunt RH
Digestion; 2008; 78 Suppl 1():31-41. PubMed ID: 18832838
[TBL] [Abstract][Full Text] [Related]
17. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn.
Kandulski A; Weigt J; Caro C; Jechorek D; Wex T; Malfertheiner P
Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1075-81. PubMed ID: 25496815
[TBL] [Abstract][Full Text] [Related]
18. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients.
Rinsma NF; Farré R; Bouvy ND; Masclee AA; Conchillo JM
Neurogastroenterol Motil; 2015 Feb; 27(2):220-8. PubMed ID: 25348594
[TBL] [Abstract][Full Text] [Related]
19. How to differentiate non-erosive reflux disease from functional heartburn.
Ke MY
J Dig Dis; 2012 Dec; 13(12):605-8. PubMed ID: 23134478
[TBL] [Abstract][Full Text] [Related]
20. Identification of Different Phenotypes of Esophageal Reflux Hypersensitivity and Implications for Treatment.
Sawada A; Guzman M; Nikaki K; Sonmez S; Yazaki E; Aziz Q; Woodland P; Rogers B; Gyawali CP; Sifrim D
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):690-698.e2. PubMed ID: 32272249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
